Turning 65 in 2026: Why the Same Eliquis, Metformin, and Atorvastatin List Costs $1,178 on One Part D Plan and $1,308 on Another
Frank Turns 65 in September. His Drug List Doesn't Care Which Plan He Picks — But His Wallet Does
Frank lives in a Las Vegas ZIP code and turns 65 on September 14, 2026. He's leaving his employer plan, where his company covered most of the premium — a benefit our employer-plan-data dataset (400 rows, sourced from the KFF Employer Health Benefits Survey) shows averages roughly 83% of premium cost for single coverage nationally. That cushion disappears the day he enrolls in Medicare.
Frank takes three drugs: Eliquis 5mg (twice daily, for atrial fibrillation), Metformin ER 1000mg (twice daily), and Atorvastatin 20mg (once daily). None of that is unusual — this exact combination shows up constantly in Pelandri's formulary comparisons, and we've written about it before in the context of zero-premium plans costing $437 more per year and Extra Help cutting the same drug list to $242/year. What's different here is the moment: Frank isn't switching plans during Open Enrollment. He's picking his first plan ever, during his Initial Enrollment Period (IEP) — the 7-month window that runs three months before his birth month, his birth month, and three months after. For Frank, that's June 1 through December 31, 2026.
Most new enrollees don't compare plans during this window. They let an insurance agent, a TV ad, or their spouse's plan decide for them. That's the exact problem the Medicare Rights Center flagged in its June 2026 policy update on private plans and information needs — beneficiaries consistently report they don't have the tools to evaluate their own formulary and cost exposure before they're locked into a plan for the year. This post is that tool, run against Frank's actual drug list.
The Three Numbers That Actually Determine Your Bill
Forget "premium" as your primary comparison point. Under the redesigned Part D benefit that's been in place since 2025, every plan is built around three numbers:
- Deductible — what you pay out of pocket before the plan starts sharing costs. The standard 2026 deductible is capped at $615, but plans can set it lower or to $0.
- Initial coverage coinsurance — after the deductible, you typically pay 25% of your drug cost until your out-of-pocket spending (called TrOOP, or True Out-of-Pocket costs) hits the annual cap.
- The $2,000 out-of-pocket cap — once your TrOOP hits $2,000 for the year, you pay nothing else for covered drugs. This replaced the old "donut hole" and "catastrophic phase" language, though you'll still see plans reference an ICL (Initial Coverage Limit) in their formulary documents out of habit.
None of those numbers show up in the plan's marketing. You have to calculate them against your own drug list — which is exactly what makes plan comparison during your IEP so error-prone without a side-by-side model.
Frank's Drug List, Full Year, Two Real Plan Designs
Based on the negotiated 2026 price for Eliquis under the IRA's Maximum Fair Price program (roughly $231/month, consistent with what we documented in Eliquis's new negotiated pricing analysis), plus standard tier-1 generic pricing of about $4/month each for Metformin and Atorvastatin, Frank's full retail annual drug cost is $2,868.
Here's what two plausible plan designs in his ZIP code — modeled against CMS marketplace formulary structures in our cms-marketplace-plans dataset (4,080 rows) and standard benefit defaults from plan-defaults (30 rows) — actually charge him over 12 months.
| Cost Component | Plan A: $0 Premium, Standard Deductible | Plan B: $62/mo Premium, $0 Deductible on Tiers 1–2 |
|---|---|---|
| Monthly premium | $0 | $62 |
| Annual premium | $0 | $744 |
| Deductible phase | $615 (paid in full, Jan–Mar) | $0 |
| Metformin + Atorvastatin (generics) | 25% coinsurance after deductible | $0 copay (waived) |
| Eliquis cost-sharing | 25% coinsurance | Flat $47/month copay |
| Total drug out-of-pocket | $1,178.25 | $564.00 |
| Total annual cost | $1,178.25 | $1,308.00 |
Plan A wins by $129.75 a year — even with the deductible — because the flat $47 Eliquis copay on Plan B doesn't offset its $744 annual premium. This is the kind of analysis Pelandri runs for you automatically, so you're not manually walking through deductible math with a calculator in one hand and a formulary PDF in the other.
The Break-Even Premium: Where Plan B Would Actually Win
Here's the part most people never calculate. Plan B's drug design saves Frank $614.25 a year compared to Plan A's coinsurance structure ($1,178.25 minus $564.00). Divide that by 12, and Plan B's premium would need to drop to $51.19/month or less to beat Plan A on total cost. At $62/month, it doesn't clear that bar. But if Frank finds a third plan in his ZIP with that same flat-copay design at, say, $45/month, the recommendation flips entirely — Plan A stops being the cheaper option.
That break-even number changes for every drug list, every ZIP code, and every plan year. You can model this for your specific situation at Pelandri instead of rebuilding this spreadsheet by hand every time a plan changes its formulary.
What Happens If Frank's Doctor Switches Him to a Generic Mid-Year?
Say Frank's cardiologist adds a fourth drug in March — brand-name Farxiga (dapagliflozin) at roughly $549/month for a heart-failure indication. Under Plan A's design, that single drug alone would push him past the $2,000 out-of-pocket cap by month five, after which the rest of the year's Farxiga, Eliquis, Metformin, and Atorvastatin would all be free for the remainder of 2026.
Now say a generic dapagliflozin becomes available and his doctor switches him in June at $42/month instead. His annual drug cost drops by roughly $6,000, but he never reaches the $2,000 cap — meaning he keeps paying 25% coinsurance on everything, all year, instead of getting six or seven months of $0 drug costs. This is the counterintuitive part of the 2025 redesign: a brand-to-generic switch lowers your total spending, but it can also delay or eliminate the point where the plan starts covering everything at no cost. Anyone switching drugs mid-year should re-run their cap math, not just assume "generic is always better" — it usually is on total dollars, but the timing shifts. Our earlier breakdown on generic sitagliptin vs. brand Januvia walks through a similar dynamic with diabetes medications.
Income Changes the Math Too — IRMAA Isn't Optional
Frank's Part D premium isn't necessarily just what the plan charges. If his modified adjusted gross income from his 2024 tax return exceeds roughly $106,000 (single) or $212,000 (married filing jointly), he owes an additional Part D-IRMAA surcharge on top of his plan premium — paid directly to Social Security, not the insurer. Based on the income brackets in our aca-subsidy-params dataset (210 rows), those surcharges for 2026 run from roughly $14 to $86 per month depending on income tier, and they apply regardless of which plan he picks. If Frank retired this year with a lower income than his working years, he can request a reconsideration using form SSA-44 rather than waiting two years for IRS data to catch up — a step Medicare Rights Center specifically flags as underused.
Enrollment Windows: Know Which One You're In
- Initial Enrollment Period (IEP): 7 months around your 65th birthday. Miss it, and you risk a permanent late-enrollment penalty.
- Annual Open Enrollment (AEP): October 15–December 7 every year, for switching plans for the following year.
- Medicare Advantage Open Enrollment (MA-OEP): January 1–March 31, for one plan switch if you're already in Medicare Advantage.
Affordability isn't an abstract policy debate for people making these choices — a recent KFF Health News analysis of Nevada's 2026 governor's race noted that healthcare affordability has become the top voter concern in swing states as federal Medicaid and SNAP changes ripple into household budgets. Whatever the policy backdrop, the plan-level math doesn't change: your total annual cost depends entirely on your specific drugs, your ZIP code's plan lineup, and your pharmacy choice.
Run Your Own Numbers Before Your Window Closes
Frank's $129.75 gap looks small next to the six-figure headlines about Medicare policy. But multiply that gap across a wrong guess on a specialty drug, a missed tier exception, or a preferred pharmacy you didn't know existed, and it turns into the $500–$2,000 swings we've documented across dozens of drug lists on this blog. Whether you're turning 65 this year or just tired of auto-renewing into a plan that quietly changed its formulary, the only way to know your real number is to run it against your actual prescriptions. That's what Pelandri is built to do — compare your drug list against every plan in your ZIP code, deductible through catastrophic cap, before your enrollment window closes.
Sources
- Affordable Healthcare Emerges as a Voter Priority in Purple Nevada — KFF Medicare
- Presentations by MedPAC staff at the 2026 AcademyHealth Annual Research Meeting and the 2026 Annual Conference of the American Society of Health Economists — MedPAC
- Newsom Vowed To Transform Kids’ Mental Health. Many California Schools Are Still Waiting. — KFF Medicare
- Priority Issues Across Medicare, Part 2: Private Plans and Information Needs — Medicare Rights Center
- Would Hunters Take a Lyme Disease Vaccine? We Asked — KFF Medicare